July 13, 2023
Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
This Vault conversation stems from the wrap-up to TLM2022. In the episode, the panel (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Ken Cusi, Wayne Eskridge and Roger Green) addresses several topics from the program. This one focuses largely on NITs.
In this conversation, Ian Rowe describes the factors that motivated him and Richard Parker to build a decision model focusing on early NASH diagnosis. He identifies three data points demonstrating how severely NASH stakeholders need a better early diagnosis paradigm and then describes the five diagnostic strategies his model will test.
This final conversation covers the other paper discussed in the episoe at large, a literature review looking at how MASH and MASLD might differ in women compared to men. Roberta starts by noting the gap in literature about gender differences in MASH studies, and that women appear represented in most clinical trials.
This conversation starts with Roger asking Roberta to describe the demographics of the population in the northwest London region where the study of interest was done. Roberta comments on the robust diversity of the population, after which Louise amplifies this point by noting the large number of Arabic and South Asian patients in the study population.
This conversation starts with your Jörn returning to a key point from Roberta’s paper around a 38% false negative rate for FIB-4 screening. Jörn notes that while this feels like a high rate for false negatives, it might not present as much of a diagnostic challenge if treaters repeat the screening every 2 to 3 years.
This week on SurfingNASH, we introduce the audience to new guest, Dr Roberta Forlano, who’s been awarded an EASL Juan Rodes PhD Fellowship and has completed a PhD in Translational Hepatology at Imperial College London in 2022.
In a recent SurfingNASH episode, Dr. Roberta Forlano, celebrated for her hepatology research and EASL Juan Rodes PhD Fellowship, delves into critical aspects of NAFLD, from screening strategies in primary care to non-invasive markers, alongside experts Jörn Schattenberg, Louise Campbell, and Roger Green. The discussions, centered on screening strategies for gender-specific SLD challenges, also showcase Roberta’s team’s notable contributions to the SLD Summit. A must-listen for those interested in advanced hepatology topics and research developments.
